- Home
- IMRN vs RLMD Comparison
IMRN vs RLMD Comparison
Compare IMRN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- RLMD
- Stock Information
- Founded
- IMRN 1994
- RLMD 2004
- Country
- IMRN Australia
- RLMD United States
- Employees
- IMRN N/A
- RLMD N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- RLMD Health Care
- Exchange
- IMRN Nasdaq
- RLMD Nasdaq
- Market Cap
- IMRN 10.3M
- RLMD 11.5M
- IPO Year
- IMRN N/A
- RLMD N/A
- Fundamental
- Price
- IMRN $1.71
- RLMD $0.40
- Analyst Decision
- IMRN Strong Buy
- RLMD Hold
- Analyst Count
- IMRN 1
- RLMD 4
- Target Price
- IMRN $5.00
- RLMD $4.25
- AVG Volume (30 Days)
- IMRN 11.8K
- RLMD 4.5M
- Earning Date
- IMRN 05-27-2025
- RLMD 05-12-2025
- Dividend Yield
- IMRN N/A
- RLMD N/A
- EPS Growth
- IMRN N/A
- RLMD N/A
- EPS
- IMRN N/A
- RLMD N/A
- Revenue
- IMRN $4,048,286.00
- RLMD N/A
- Revenue This Year
- IMRN N/A
- RLMD N/A
- Revenue Next Year
- IMRN N/A
- RLMD N/A
- P/E Ratio
- IMRN N/A
- RLMD N/A
- Revenue Growth
- IMRN 82.90
- RLMD N/A
- 52 Week Low
- IMRN $1.60
- RLMD $0.24
- 52 Week High
- IMRN $2.87
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- IMRN 41.94
- RLMD 51.73
- Support Level
- IMRN $1.87
- RLMD $0.36
- Resistance Level
- IMRN $2.13
- RLMD $0.44
- Average True Range (ATR)
- IMRN 0.15
- RLMD 0.08
- MACD
- IMRN -0.01
- RLMD -0.00
- Stochastic Oscillator
- IMRN 32.71
- RLMD 26.98
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.